Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CALC | US
-0.10
-9.62%
Healthcare
Biotechnology
30/06/2024
08/06/2026
0.96
1.06
1.06
0.91
CalciMedica Inc. a clinical-stage biotechnology company focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis asparaginase-associated acute pancreatitis and acute kidney injury. The company is based in La Jolla California.
View LessWeakness based on declining price with high volume
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
189.9%1 month
147.7%3 months
118.5%6 months
166.1%-
-
3.17
-
-
-0.26
-
-
-21.39M
10.30M
10.30M
-
-
-
-
-83.76
0.65
0.65
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.48
Range1M
0.54
Range3M
0.61
Rel. volume
1.74
Price X volume
520.48K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Lipocine Inc | LPCN | Drug Manufacturers-Specialty & Generic | 2.04 | 10.91M | -0.49% | n/a | 0.00% |
| Longeveron Inc. Class A Common Stock | LGVN | Biotechnology | 0.754 | 10.83M | 3.29% | n/a | 11.72% |
| Cocrystal Pharma Inc | COCP | Biotechnology | 1.01 | 10.28M | 4.74% | n/a | 10.24% |
| Lexaria Bioscience Corp | LEXX | Biotechnology | 0.6466 | 10.22M | 1.51% | n/a | 1.41% |
| VYNE Therapeutics Inc | VYNE | Biotechnology | 0.6586 | 9.71M | 0.38% | 1.29 | 0.19% |
| Hoth Therapeutics Inc | HOTH | Biotechnology | 1.36 | 9.39M | -9.93% | n/a | 0.44% |
| Anebulo Pharmaceuticals Inc. Common Stock | ANEB | Biotechnology | 0.3602 | 9.34M | -3.95% | n/a | 0.00% |
| KPRX | KPRX | Biotechnology | 2.58 | 7.66M | 3.20% | 0.21 | 0.25% |
| Cyclerion Therapeutics Inc | CYCN | Biotechnology | 3.01 | 7.57M | 1.01% | n/a | 0.00% |
| Immuron Limited | IMRN | Biotechnology | 1.2 | 7.29M | -4.00% | n/a | 1.37% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.4131 | 7.98M | -3.48% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.49 | 3.81M | 12.88% | n/a | 17.32% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0058 | 534.84K | n/a | -37.05% | |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4181 | 230.37K | 7.87% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.26 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.17 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 118.49 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 10.30M | 3.66B | Emerging |